Invivyd IVVD
NASDAQ IVVD
$0.60 +0.02 (+4.01%)
As of: Nov 11, 2026 · 3:59 PM EST

Invivyd (IVVD) EBITDA Margin (2024 - 2026)

Updated

Invivyd (IVVD) posted EBITDA Margin of -72.10% for Q4 2025, up 59.20 percentage points from -131.30% a year earlier and up 10.73 percentage points from the prior quarter.

Analysis

Invivyd (IVVD) EBITDA Margin (2024 - 2026) Analysis & Trends

For FY2025, Invivyd's EBITDA Margin came in at -102.58%, up 588.44 percentage points from FY2024.

  • In prior years, Invivyd's EBITDA Margin was -691.03% in FY2024.
  • On a year-over-year basis, EBITDA Margin has increased in each of the last three quarters.
  • According to Business Quant data, EBITDA Margin for the three prior quarters was -82.82% (Q3 2025), -126.50% (Q2 2025) and -146.99% (Q1 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 36.69%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 32.68%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 46.88%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 40.60%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 39.77%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 46.62%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 50.63%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 42.49%
10 Invivyd 168.01 Mn -487.88 Mn 13.01 Mn -319.50%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -319.50%
Mar 31, 2026 -312.63%
Dec 31, 2025 -72.10%
Sep 30, 2025 -82.82%
Jun 30, 2025 -126.50%
Mar 31, 2025 -146.99%
Dec 31, 2024 -131.30%
Sep 30, 2024 -668.59%
Jun 30, 2024 -2,169.57%
API Access

Invivyd EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=IVVD&period=max&api_key=YOUR_API_KEY